Market Mover: Evaxion A/S (EVAX) Up at Midday June 21

Equities Staff  |

Evaxion Biotech A/S - ADR (NASDAQ: EVAX) has risen $0.195 (12.19%) and is currently sitting at $1.80, as of 11:48:52 est on June 21.

51,728 shares have been traded today.

The Company has fallen 6.43% over the last 5 days and shares have fallen 13.98% over the last 30 days.

Evaxion A/S is set to release earnings on 2022-08-11.

For technical charts, analysis, and more on Evaxion A/S visit the company profile.

About Evaxion Biotech A/S - ADR

Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus. or MRSA) induced skin and soft tissue infections.

To get more information on Evaxion Biotech A/S - ADR and to follow the company's latest updates, you can visit the company's profile page here: Evaxion Biotech A/S - ADR's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade

Market Movers

Sponsored Financial Content